With over 100,000 patients with gastric conditions across our global network,We are one of the services that contributed to the American Association for the Study of Liver Diseases (AASLD) Conference.

During the conference, the paper, “VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial”, which was co-authored by Medical Director Dr. Randall Severance, was discussed in a late breaking abstract oral session.

What did the session cover?

The session explored the background, methods and results of one of our many clinical trials: a 12-week test of VK2809, a small molecule prodrug of a potent thyroid beta receptor agonist, in human patients with NAFLD and elevated LDL cholesterol (LDL-C).

It began by offering some context to how the study originated, and then outlined the instrumental role of the thyroid hormone in regulating lipid metabolism. This suggests VK2809’s potential therapeutic benefits.

The multi-centre, randomised, double-blind, placebo-controlled, Phase 2a clinical trial was conducted to evaluate the safety, tolerability and efficacy of VK2809. Patients received either oral VK2809 doses of 10 mg QOD, or 10 mg QD, or a placebo for 12 weeks.

What were the results?

Patients that received VK2809 demonstrated statistically significant reductions in LDL-C of 20% or more compared with placebo-treated patients.

They also experienced statistically significant reductions in liver fat content, as assessed by magnetic resonance imaging proton density fat fraction, relative to the placebo.


Overall, a 12-week course of treatment with VK2809 resulted in significant reductions in LDL-C – with a series of robust improvements in liver fat content in NAFLD patients.

The conclusive data appears to advocate continued use of VK2809 as a potential treatment for patients with biopsy-proven NASH with fibrosis, and this is an area which was discussed in deeper detail with AASLD audience members.

The study is further example of our success in the field of clinical studies aimed at discovering potential liver function enhancement solutions. For more information about the Liver Meeting, head over to the AASLD website. To discuss the role we played within it, get in touch with our team via our contact page.